TScan Therapeutics Reports Financial Results and Progress on TCR-T Therapies

WALTHAM, Mass. – TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology firm, announced its financial results for the second quarter ending June 30, 2024, alongside updates on its T cell receptor-engineered T cell (TCR-T) therapies. The company is on track to release initial data from its solid tumor program and one-year data from the ALLOHA Phase 1 heme trial by the end of 2024. CEO Gavin MacBeath highlighted the significance of receiving RMAT designation from the FDA for its lead candidates, TSC-100 and TSC-101, aimed at treating hematologic malignancies. The ALLOHA trial focuses on preventing relapse in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndromes (MDS) following allogeneic hematopoietic cell transplantation. TScan anticipates reporting clinical and translational data for initial patients by year-end 2024, with multiplex therapy response data expected in 2025. The company reported a $5.7 million increase in clinical study expenses, driven by ongoing trial enrollments and expanded research activities. As of June 30, 2024, TScan's cash position stood at $297.7 million, excluding restricted cash. The company continues to develop its ImmunoBank, a repository of therapeutic TCRs, to create customized multiplex TCR-T therapies for various cancers. TScan's forward-looking statements indicate optimism about its clinical programs, though they acknowledge inherent risks and uncertainties in the biotechnology sector. The company remains focused on advancing its TCR-T therapy candidates and expanding its market presence, while also navigating the complexities of regulatory requirements and competitive dynamics in the industry.